8-K: Jaguar Health Stockholders Approve Key Proposals

Jaguar Health, Inc. announced the approval of all three proposals at its Special Meeting of Stockholders, including the issuance of shares related to Series N Preferred Stock and a new PIPE offering.

Summary

• A Special Meeting of Stockholders was held on December 8, 2025, where three proposals were submitted and approved.
• Proposal 1, to approve the issuance of Common Stock upon exchange and/or redemption of Series N Preferred Stock for Nasdaq Listing Rule 5635(d) purposes, was approved with 1,032,716 votes For, 73,065 Against, and 14,633 Abstained.
• Proposal 2, to approve the issuance of New PIPE Shares and a Pre-Funded PIPE Warrant pursuant to a securities purchase agreement dated September 28, 2025, for Nasdaq Rule 5635(d) purposes, was approved with 2,049,724 votes For, 71,765 Against, and 12,805 Abstained.
• Proposal 3, to approve one or more adjournments of the Special Meeting if necessary to solicit additional proxies, was approved with 2,058,277 votes For, 61,460 Against, and 14,557 Abstained.
• Initial results from an ongoing investigator-initiated proof-of-concept trial demonstrate that crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of total parenteral support (PS) necessary by up to 37%, though with associated toxicity.
• The company completed a meeting with the FDA on October 2, 2025, to seek advice on advancing its ongoing placebo-controlled trial of crofelemer in support of a possible expedited approval pathway for MVID.
• Jaguar CEO Lisa Conte is scheduled to present at the Emerging Growth Conference on December 8, 2025, to provide updates on near-term catalysts.

Sentiment

Score: 7

Explanation: The approval of all proposals provides corporate stability and enables planned financing. The initial positive, albeit qualified, clinical trial results for crofelemer in MVID, coupled with FDA engagement for an expedited pathway, are significant positives for a company focused on drug development, despite the mention of associated toxicity.

Positives

• All three proposals submitted to stockholders were approved, providing corporate stability and enabling planned financing activities.
• Initial proof-of-concept trial results for crofelemer in Microvillus Inclusion Disease (MVID) show potential to extend lives of infants and reduce total parenteral support volume by up to 37%.
• The company engaged with the FDA on October 2, 2025, for advice on advancing the crofelemer trial for MVID, indicating progress towards potential expedited approval.
• Crofelemer addresses a significant unmet medical need as no approved treatments currently exist for MVID.

Negatives

• The initial proof-of-concept trial for crofelemer in MVID noted associated toxicity, which could impact future development or approval.
• Voting caps (9.99% or 19.99%) on Series L, M, and N Preferred Stock limit the voting power of certain holders.

Risks

• Forward-looking statements are subject to various risks, uncertainties, and assumptions, some of which are unpredictable or beyond the company's control.
• The expectation that crofelemer can potentially extend lives or reduce PS volume in MVID is not guaranteed and is subject to further clinical trial outcomes.
• The possibility of an expedited approval pathway for crofelemer for MVID treatment is an expectation and not a certainty.
• Associated toxicity observed in the MVID trial could pose challenges for further development, regulatory approval, or commercialization.

Future Outlook

The company expects crofelemer to potentially extend the lives of infants with Microvillus Inclusion Disease (MVID) and reduce the volume of total parenteral support. It also anticipates a possible expedited approval pathway for crofelemer for MVID treatment following discussions with the FDA. Management will present updates on near-term catalysts at an upcoming conference.

Management Comments

• Jaguar CEO Lisa Conte is presenting on December 8, 2025, from 3:25pm 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts.

Industry Context

The development of crofelemer for Microvillus Inclusion Disease (MVID) addresses a significant unmet medical need, as no approved treatments currently exist for this rare, life-threatening orphan disease. This aligns with a broader industry trend of pharmaceutical companies focusing on orphan drug development, which often benefits from expedited regulatory pathways and extended market exclusivity due to the high medical need and smaller patient populations. The associated toxicity observed in the trial highlights common challenges in drug development, particularly for severe conditions in vulnerable populations like infants.

Corporate Governance

Stakeholder Impact

• Shareholders: The approval of proposals allows for potential dilution from the PIPE offering and preferred stock conversions but also provides capital for operations and drug development. The voting caps on preferred stock affect the relative voting power of different shareholder classes.
• Patients (MVID): Initial positive results for crofelemer offer hope for a new treatment option for a severe, currently untreatable condition, potentially extending lives and improving quality of life, despite noted toxicity.

Next Steps

• Lisa Conte will present at the Emerging Growth Conference on December 8, 2025, to provide updates on near-term catalysts.
• The company plans to advance its ongoing placebo-controlled trial of crofelemer for MVID.
• The company intends to pursue a possible expedited approval pathway for crofelemer for MVID treatment.

Key Dates

Recommendation

While the approval of proposals and initial positive clinical trial data for crofelemer in MVID are encouraging, the associated toxicity and the early stage of the MVID trial (proof-of-concept) introduce significant uncertainty. The capital raise via PIPE, while necessary, also implies potential dilution. Investors should hold to monitor further clinical trial progress, especially regarding the toxicity profile and the path to expedited FDA approval, before making further investment decisions.

Keywords

Jaguar Health, JAGX, Stockholder Meeting, Proxy Vote, Nasdaq Listing Rule 5635(d), PIPE Offering, Preferred Stock, Common Stock, Crofelemer, MVID, Microvillus Inclusion Disease, FDA, Orphan Disease, Pharmaceuticals, Biotechnology, Clinical Trial, Corporate Governance